CN114391013A - 一种irak抑制剂及其制备方法和用途 - Google Patents

一种irak抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN114391013A
CN114391013A CN202080062424.4A CN202080062424A CN114391013A CN 114391013 A CN114391013 A CN 114391013A CN 202080062424 A CN202080062424 A CN 202080062424A CN 114391013 A CN114391013 A CN 114391013A
Authority
CN
China
Prior art keywords
compound
formula
reaction
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080062424.4A
Other languages
English (en)
Other versions
CN114391013B (zh
Inventor
野国中
丁陈利
丁雅雯
贺潜
王朝东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Meiyue Biotech Development Co Ltd
Original Assignee
Shanghai Meiyue Biotech Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Meiyue Biotech Development Co Ltd filed Critical Shanghai Meiyue Biotech Development Co Ltd
Publication of CN114391013A publication Critical patent/CN114391013A/zh
Application granted granted Critical
Publication of CN114391013B publication Critical patent/CN114391013B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

公开了一种式I所示的化合物、其立体异构体、消旋体、互变异构体、同位素标记物、前药或其药学上可接受的盐，以及包含其的药物组合物，其制备方法，及其医药用途，所述结构如式I。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080062424.4A 2019-09-24 2020-09-23 一种irak抑制剂及其制备方法和用途 Active CN114391013B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910906833 2019-09-24
CN2019109068337 2019-09-24
PCT/CN2020/117093 WO2021057785A1 (zh) 2019-09-24 2020-09-23 一种irak抑制剂及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN114391013A true CN114391013A (zh) 2022-04-22
CN114391013B CN114391013B (zh) 2024-01-26

Family

ID=75165579

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080062424.4A Active CN114391013B (zh) 2019-09-24 2020-09-23 一种irak抑制剂及其制备方法和用途

Country Status (22)

Country Link
US (1) US20220298139A1 (zh)
EP (1) EP4015513B1 (zh)
JP (1) JP7353474B2 (zh)
KR (1) KR20220035450A (zh)
CN (1) CN114391013B (zh)
AU (1) AU2020352311B2 (zh)
BR (1) BR112022001568A2 (zh)
CA (1) CA3152167C (zh)
CL (1) CL2022000725A1 (zh)
CO (1) CO2022004978A2 (zh)
DO (1) DOP2022000054A (zh)
EC (1) ECSP22032016A (zh)
ES (1) ES2967642T3 (zh)
HR (1) HRP20240122T1 (zh)
IL (1) IL291158A (zh)
LT (1) LT4015513T (zh)
MX (1) MX2022003504A (zh)
PE (1) PE20220944A1 (zh)
PT (1) PT4015513T (zh)
TW (1) TWI832010B (zh)
WO (1) WO2021057785A1 (zh)
ZA (1) ZA202204441B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4155302A4 (en) * 2020-06-23 2023-11-22 Shanghai Meiyue Biotech Development Co., Ltd. METHOD FOR PREPARING A CONDENSED PYRAZOLE-TYPE COMPOUND
AU2022239519A1 (en) * 2021-03-19 2023-10-05 Shanghai Meiyue Biotech Development Co., Ltd. Polymorphic forms of compound and preparation method therefor and application thereof
CN114404415A (zh) * 2022-02-25 2022-04-29 上海美悦生物科技发展有限公司 吲唑类化合物用于治疗银屑病的用途
CN115252609B (zh) * 2022-08-01 2023-05-26 上海美悦生物科技发展有限公司 一种irak4抑制剂的组合物及其制备方法、用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016083433A1 (de) * 2014-11-26 2016-06-02 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
WO2017108744A1 (de) * 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017148902A1 (de) * 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017207481A1 (en) * 2016-06-01 2017-12-07 Bayer Animal Health Gmbh Substituted indazoles ueful for treatment and prevention of allergic and/or inflammatory diseases in animals
WO2017207385A1 (de) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2020135513A1 (zh) * 2018-12-25 2020-07-02 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111499612A (zh) * 2019-01-30 2020-08-07 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1038586C (zh) * 1991-05-01 1998-06-03 大制药株式会社 吡嗪衍生物的制备方法
TW201422606A (zh) 2012-11-08 2014-06-16 必治妥美雅史谷比公司 可作爲激酶調節劑之經雙環雜環取代之吡啶化合物
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
SG11202002386WA (en) 2017-10-31 2020-04-29 Curis Inc Compounds and compositions for treating hematological disorders
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4155302A4 (en) * 2020-06-23 2023-11-22 Shanghai Meiyue Biotech Development Co., Ltd. METHOD FOR PREPARING A CONDENSED PYRAZOLE-TYPE COMPOUND

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016083433A1 (de) * 2014-11-26 2016-06-02 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
WO2017108744A1 (de) * 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017148902A1 (de) * 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017207385A1 (de) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017207481A1 (en) * 2016-06-01 2017-12-07 Bayer Animal Health Gmbh Substituted indazoles ueful for treatment and prevention of allergic and/or inflammatory diseases in animals
WO2020135513A1 (zh) * 2018-12-25 2020-07-02 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111499612A (zh) * 2019-01-30 2020-08-07 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
袁开基等编, 人民卫生出版社 *

Also Published As

Publication number Publication date
ECSP22032016A (es) 2022-05-31
TWI832010B (zh) 2024-02-11
CN114391013B (zh) 2024-01-26
CA3152167C (en) 2023-12-19
PE20220944A1 (es) 2022-05-31
JP7353474B2 (ja) 2023-09-29
AU2020352311B2 (en) 2023-11-09
CL2022000725A1 (es) 2022-11-18
WO2021057785A1 (zh) 2021-04-01
CO2022004978A2 (es) 2022-04-29
MX2022003504A (es) 2022-07-19
EP4015513A4 (en) 2022-09-14
ES2967642T3 (es) 2024-05-03
KR20220035450A (ko) 2022-03-22
US20220298139A1 (en) 2022-09-22
BR112022001568A2 (pt) 2022-03-22
ZA202204441B (en) 2022-11-30
EP4015513A1 (en) 2022-06-22
LT4015513T (lt) 2023-12-11
HRP20240122T1 (hr) 2024-04-12
EP4015513B1 (en) 2023-11-01
JP2022549870A (ja) 2022-11-29
AU2020352311A1 (en) 2022-04-14
TW202115015A (zh) 2021-04-16
IL291158A (en) 2022-05-01
PT4015513T (pt) 2023-12-19
CA3152167A1 (en) 2021-04-01
DOP2022000054A (es) 2022-07-15

Similar Documents

Publication Publication Date Title
JP7054721B2 (ja) Ｂｔｋ阻害剤としての４－イミダゾピリダジン－１－イル－ベンズアミドおよび４－イミダゾトリアジン－１－イル－ベンズアミド
CN114391013B (zh) 一种irak抑制剂及其制备方法和用途
US10336697B2 (en) Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
CN105566321B (zh) 杂芳化合物及其在药物中的应用
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
BR112014029851B1 (pt) Composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, agente para tratamento de um tumor, e uso do referido composto
EP3784671B1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
KR20220119455A (ko) T 세포 활성화제로서 유용한 치환된 비시클릭 피페리딘 유도체
CN111683662A (zh) 取代嘧啶类化合物及其药物组合物和治疗方法
CN111560012A (zh) 一种作为irak抑制剂的化合物
CA3200620A1 (en) Aromatic heterocyclic compound, and pharmaceutical composition and application thereof
CN111499612B (zh) 一种作为irak抑制剂的化合物及其制备方法和用途
CN109651358B (zh) 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
EP4186901A1 (en) Compound having kinase inhibitory activity
CN111718332B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN111793064A (zh) 一种作为irak抑制剂的化合物及其制备方法和用途
CN113727984A (zh) 大环类衍生物、及其制备方法和用途
EA044151B1 (ru) Ингибитор irak и способ его получения и применения
CN112521372B (zh) 一种细胞凋亡蛋白抑制剂及其制备方法和用途
CN114790164B (zh) 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
WO2023212147A1 (en) Heterocyclic compounds as modulators of bcl6 as ligand directed degraders
TW202225162A (zh) 芳香雜環類化合物、藥物組合物及其應用
CN113493438A (zh) 四氢异喹啉类化合物
CN114853679A (zh) 一种苯并咪唑类enl蛋白抑制剂及其制备方法和用途
CN115594622A (zh) 一种吡咯磺酰类衍生物、及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063236

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant